The Company assists physicians by maximizing personalized treatment options for their cancer patients through access to expert medical information panels and tumor specific data.

The Company administers expert medical panels with participants that are selected based on the patient’s specific cancer type and condition. A panel typically includes renowned experts from each of the disciplines that may be critical to the patient’s status and treatment including oncologists, radiologists, surgeons, pathologists and expert researchers from both academia and the pharmaceutical/biotechnology industry. Experts review various regional and international treatment approaches designed to maximize options available to the treating physician. The medical panel’s goal is to assist the physician by: (i) analyzing prior medical records and test results, (ii) recommending specialized testing, analysis and interpretation of data from the patient’s cancer tissues, if appropriate, and (iii) assisting in evaluating both conventional and novel research and treatment options.

Physicians may also have the opportunity to arrange development of Personalized Tumorgrafts from their patient’s tumor. To accomplish this, the physician may obtain a sample of the patient’s tumor to be immediately implanted in immune deficient mice and propagated in a manner that preserves the biological properties of the original tumor. Development of the Personalized Tumorgrafts may enable extensive in vivo testing of numerous novel and standard drugs and drug combinations. This targeted process typically provides data regarding the drug/drug combinations that are the least and most effective. This data may be useful to the patient’s physician in evaluating future treatment options for the patient.